NBSE - NeuBase Therapeutics, Inc. Stock Price and Quote

NBSE [NASD]

Index	-	P/E	-	EPS (ttm)	-1.04	Insider Own	2.50%	Shs Outstand	32.28M	Perf Week	6.32%
Market Cap	7.74M	Forward P/E	-	EPS next Y	-0.33	Insider Trans	0.00%	Shs Float	30.02M	Perf Month	3.46%
Income	-33.80M	PEG	-	EPS next Q	-0.15	Inst Own	37.20%	Short Float / Ratio	1.01% / 1.11	Perf Quarter	-11.38%
Sales	-	P/S	-	EPS this Y	-11.70%	Inst Trans	-6.04%	Short Interest	0.30M	Perf Half Y	-81.38%
Book/sh	0.72	P/B	0.33	EPS next Y	26.70%	ROA	-75.70%	Target Price	7.00	Perf Year	-83.86%
Cash/sh	0.72	P/C	0.33	EPS next 5Y	4.00%	ROE	-97.30%	52W Range	0.17 - 2.08	Perf YTD	27.29%
Dividend	-	P/FCF	-	EPS past 5Y	37.20%	ROI	-	52W High	-88.36%	Beta	1.05
Dividend %	-	Quick Ratio	5.90	Sales past 5Y	-	Gross Margin	-	52W Low	40.75%	ATR	0.03
Employees	37	Current Ratio	5.90	Sales Q/Q	-	Oper. Margin	-	RSI (14)	51.32	Volatility	12.49% 13.31%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	-8.30%	Profit Margin	-	Rel Volume	0.23	Prev Close	0.24
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Dec 22 AMC	Payout	-	Avg Volume	275.20K	Price	0.24
Recom	3.00	SMA20	-1.98%	SMA50	7.38%	SMA200	-61.39%	Volume	34,566	Change	0.88%

Feb-12-21

Reiterated

H.C. Wainwright

Buy

$15 → $18

Jun-16-20

Initiated

RBC Capital Mkts

Outperform

$16

Feb-07-20

Initiated

Guggenheim

Buy

Feb-06-20

Initiated

Guggenheim

Buy

Nov-21-19

Initiated

Oppenheimer

Outperform

$14

Sep-24-19

Initiated

BTIG Research

Buy

$15

Dec-29-22 05:53PM	NeuBase Therapeutics selling stake in company to New York investment firm Alumni Capital American City Business Journals
Dec-21-22 08:00AM	NeuBase Therapeutics Reports Business Update and Financial Results for Fiscal Year 2022 GlobeNewswire +5.37%
Oct-21-22 08:00AM	NeuBase Therapeutics Announces Gene Editing Research Agreement with Global Healthcare Company GlobeNewswire
Oct-14-22 04:05PM	NeuBase Therapeutics Announces Strategic Restructuring Focused on Advancing Its Platform in Gene Editing GlobeNewswire -9.73%
Sep-22-22 04:05PM	NeuBase to Participate at Chardans 6th Annual Genetic Medicines Conference GlobeNewswire -11.49%
08:00AM	Loading…
Aug-11-22 08:00AM	NeuBase Therapeutics Reports Business Update and Financial Results for the Third Quarter of Fiscal Year 2022 GlobeNewswire
Aug-08-22 09:57AM	We Think NeuBase Therapeutics (NASDAQ:NBSE) Needs To Drive Business Growth Carefully Simply Wall St.
Jun-29-22 08:01AM	NeuBase Therapeutics Announces Promotion of Dr. William Mann to President and COO GlobeNewswire +8.69%
Jun-01-22 07:00AM	NeuBase to Participate at the Jefferies Healthcare Conference GlobeNewswire
May-17-22 07:00AM	NeuBase Presents New Preclinical Data at ASGCT 2022 for Its DM1 Program Demonstrating Wide Tissue Distribution and Supporting a Differentiated Whole-Body Treatment Solution GlobeNewswire +7.29%
May-12-22 05:00PM	NeuBase Therapeutics Reports Business Update and Financial Results for the Second Quarter of Fiscal Year 2022 GlobeNewswire
10:53AM	Insiders who bought in the last 12 months lose an additional US$65k as NeuBase Therapeutics, Inc. (NASDAQ:NBSE) drops to US$29m Simply Wall St.
May-02-22 04:30PM	NeuBase Therapeutics Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) 2022 Annual Meeting GlobeNewswire
Mar-13-22 07:00PM	NeuBase Therapeutics Presents New Preclinical Data at MDA 2022 for Its Myotonic Dystrophy Type 1 Program Demonstrating Splice Rescue, Nuclear Aggregate Resolution, and Myotonia Reversal GlobeNewswire
Mar-07-22 08:00AM	NeuBase to Present at Oppenheimers 32nd Annual Healthcare Conference GlobeNewswire -10.32%
08:00AM	Loading…
Feb-28-22 08:00AM	NeuBase Therapeutics to Present New Preclinical Data for Myotonic Dystrophy Type 1 Program at the 2022 MDA Clinical & Scientific Conference GlobeNewswire
Feb-10-22 07:00PM	NeuBase Therapeutics Reports Business Update and Financial Results for the First Quarter of Fiscal Year 2022 GlobeNewswire -12.08%
Feb-01-22 10:44AM	Is NeuBase Therapeutics (NASDAQ:NBSE) In A Good Position To Invest In Growth? Simply Wall St. +13.16%
Jan-11-22 11:34AM	NeuBase Therapeutics hires new chief financial officer American City Business Journals
Jan-10-22 04:02PM	NeuBase Therapeutics Appoints Todd P. Branning Chief Financial Officer GlobeNewswire
Jan-05-22 04:02PM	NeuBase Therapeutics Appoints Dr. Eric J. Ende to Board of Directors GlobeNewswire -10.34%
Dec-23-21 04:01PM	NeuBase Therapeutics Reports Business Update and Financial Results for Fiscal Year 2021 GlobeNewswire +5.52%
Nov-03-21 04:05PM	NeuBase to Present at the Jefferies London Healthcare Conference GlobeNewswire
Nov-01-21 01:12PM	Quite a few insiders invested in NeuBase Therapeutics, Inc. (NASDAQ:NBSE) last year which is positive news for shareholders Simply Wall St.
Oct-05-21 08:00AM	VBL Therapeutics Announces Appointment of Sam Backenroth as Chief Financial Officer and Establishes Operations in the United States GlobeNewswire
Sep-28-21 04:05PM	NeuBase to Participate at the Chardan 5th Annual Genetic Medicines Conference GlobeNewswire
Sep-21-21 04:54PM	Pittsburgh-based biotech company on a growth path American City Business Journals
Sep-15-21 04:05PM	NeuBase to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit GlobeNewswire
Sep-14-21 08:00AM	NeuBase Therapeutics Appoints Anthony Rossomando, Ph.D. as Chief Technology Officer GlobeNewswire
Sep-01-21 04:05PM	NeuBase Therapeutics to Present Virtually at the H.C. Wainwright 23rd Annual Global Investment Conference GlobeNewswire
08:45AM	Loading…
Aug-31-21 08:45AM	What Type Of Shareholders Make Up NeuBase Therapeutics, Inc.'s (NASDAQ:NBSE) Share Registry? Simply Wall St. +8.72%
Aug-12-21 04:01PM	NeuBase Therapeutics Reports Financial Results for the Third Quarter of Fiscal Year 2021 and Recent Operating Highlights GlobeNewswire
Jun-30-21 05:07AM	We're Hopeful That NeuBase Therapeutics (NASDAQ:NBSE) Will Use Its Cash Wisely Simply Wall St.
Jun-08-21 12:30PM	NeuBase Therapeutics Demonstrates Functional Rescue in Myotonic Dystrophy Type 1 Model and Allele-Selective Inhibition of KRAS Mutations to Inhibit Tumor Growth GlobeNewswire
Jun-02-21 09:00AM	NeuBase Therapeutics Announces Speakers for Virtual R&D Day Taking Place on June 8th GlobeNewswire
May-25-21 08:00AM	NeuBase Therapeutics Appoints Dr. Kia Motesharei Chief Business and Strategy Officer GlobeNewswire
May-20-21 08:00AM	NeuBase Therapeutics Appoints Dr. Sandra Rojas-Caro Chief Medical Officer GlobeNewswire
May-14-21 12:31PM	NeuBase Therapeutics to Participate in Upcoming Investor Conferences in May 2021 GlobeNewswire +9.48%
May-13-21 04:05PM	NeuBase Therapeutics Reports Financial Results for the Second Quarter of Fiscal Year 2021 GlobeNewswire
May-12-21 09:00AM	NeuBase Therapeutics Appoints Gerald J. McDougall to Board of Directors GlobeNewswire
Apr-28-21 04:27AM	Insider Buying: The NeuBase Therapeutics, Inc. (NASDAQ:NBSE) Independent Director Just Bought 120% More Shares Simply Wall St. +9.68%
Apr-27-21 08:00AM	NeuBase Therapeutics to Present at the B. Riley Securities Virtual Neuroscience Conference GlobeNewswire
Apr-26-21 04:01PM	NeuBase Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Apr-22-21 09:07AM	NeuBase Therapeutics Announces Pricing of $40 Million Public Offering of Common Stock GlobeNewswire -5.00%
Apr-21-21 04:01PM	NeuBase Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire
Apr-14-21 07:00AM	Coya Therapeutics Announces the Appointment of Hideki Garren, M.D., Ph.D., and Dov Goldstein, M.D., to Its Board of Directors GlobeNewswire
Apr-08-21 08:00AM	NeuBase Therapeutics to Host a Virtual R&D Day on June 8th to Provide Updates on the Drug Development Pipeline Targeting Genetic Diseases GlobeNewswire
Mar-19-21 05:33AM	Here's What NeuBase Therapeutics, Inc.'s (NASDAQ:NBSE) Shareholder Ownership Structure Looks Like Simply Wall St.
Mar-16-21 08:00AM	NeuBase Therapeutics to Present at the 2021 Muscular Dystrophy Association Virtual Clinical & Scientific Conference GlobeNewswire -8.07%
Mar-09-21 07:00AM	NeuBase Therapeutics to Present at Upcoming Investor Conferences in March 2021 GlobeNewswire
Feb-11-21 04:01PM	NeuBase Therapeutics Reports Financial Results for the First Quarter of Fiscal Year 2021 GlobeNewswire
Jan-28-21 08:00AM	NeuBase Therapeutics Announces Acquisition of Gene Modulating Technology from Vera Therapeutics GlobeNewswire
Jan-22-21 12:14AM	Is Neubase Therapeutics (NBSE) Stock a Buy For 2021? Insider Monkey +16.53%
Jan-11-21 06:00AM	NeuBase Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference GlobeNewswire
Dec-23-20 04:05PM	NeuBase Therapeutics Reports Business Update and Financial Results for Fiscal Year 2020 GlobeNewswire
Dec-18-20 11:35AM	NeuBase Therapeutics' CEO, Dietrich A. Stephan, Ph.D., to Present "Accelerating the Genetic Revolution with a New Class of Synthetic Medicines" at Tribe Public's Event on December 22, 2020 ACCESSWIRE
Dec-16-20 06:30AM	NeuBase Therapeutics Announces Positive Preclinical In Vivo Data for PATrOL-enabled Anti-gene for the Treatment of Myotonic Dystrophy Type 1 GlobeNewswire +12.67%
Dec-02-20 06:23PM	Here is What Hedge Funds Think About NeuBase Therapeutics, Inc. (NBSE) Insider Monkey +7.62%
08:00AM	NeuBase Therapeutics Announces Appointment of Curt Bradshaw, Ph.D. as Chief Scientific Officer GlobeNewswire
Nov-23-20 08:00AM	NeuBase Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire
Nov-18-20 01:46AM	Did NeuBase Therapeutics, Inc. (NASDAQ:NBSE) Insiders Buy Up More Shares? Simply Wall St.
Nov-17-20 08:00AM	NeuBase Therapeutics Announces Addition of Eriks Rozners, Ph.D. and Randy Davis, MBA to Scientific Advisory Board GlobeNewswire
Nov-10-20 08:00AM	NeuBase Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference on Tuesday, November 17 GlobeNewswire
Oct-26-20 08:15AM	NeuBase Therapeutics' CEO, Dietrich A. Stephan, Ph.D., to Present "Manufacturing Heat-Seeking Missiles Against Misbehaving Genes" at Tribe Public's Event on October 28, 2020 ACCESSWIRE
Oct-20-20 10:09AM	Oppenheimer: These 2 Stocks Could Double, If Not More TipRanks +7.66%
Oct-13-20 08:00AM	NeuBase Therapeutics Announces Addition of Peter Nielsen, Ph.D., Inventor of Peptide Nucleic Acid Technology, to Scientific Advisory Board GlobeNewswire +8.70%
Sep-28-20 08:00AM	NeuBase Therapeutics to Present at the Chardan Virtual 4th Annual Genetic Medicines Conference on Monday, October 5th GlobeNewswire
Sep-17-20 08:30AM	NeuBase Therapeutics to Present at the Myotonic Dystrophy Foundation 2020 Virtual Conference GlobeNewswire
Sep-08-20 08:00AM	NeuBase Therapeutics to Present at Upcoming Investor Conferences in September 2020 GlobeNewswire +6.32%
Aug-31-20 05:00PM	(LD Micro) 360 Companies Set to Present this Week ACCESSWIRE
Aug-24-20 05:00PM	NeuBase Therapeutics CEO, Dietrich A. Stephan, Ph.D., to Present at Tribe Publics Presentation and Q&A Webinar Event on August 26, 2020 ACCESSWIRE
Aug-20-20 01:09PM	What Kind Of Investors Own Most Of NeuBase Therapeutics, Inc. (NASDAQ:NBSE)? Simply Wall St.
Aug-13-20 04:01PM	NeuBase Therapeutics Reports Financial Results for the Third Fiscal Quarter of 2020 GlobeNewswire
Aug-06-20 01:43PM	LD Micro: Announces Preliminary List of Presenters for the LD-500 ACCESSWIRE
Jun-10-20 04:20PM	Is NeuBase Therapeutics, Inc. (NBSE) A Good Stock To Buy? Insider Monkey
May-15-20 08:48AM	Need To Know: NeuBase Therapeutics, Inc. (NASDAQ:NBSE) Insiders Have Been Buying Shares Simply Wall St.
Apr-30-20 04:05PM	NeuBase Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Apr-28-20 09:44AM	NeuBase Therapeutics Announces Pricing of $31,500,000 Public Offering of Common Stock GlobeNewswire -6.98%
Apr-27-20 04:01PM	NeuBase Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire +5.69%
Mar-31-20 07:01AM	NeuBase Therapeutics Announces Positive, Preclinical Data Validating its Novel Genetic Therapy PATrOL Platform GlobeNewswire +14.29%
Dec-02-19 08:00AM	NeuBase Therapeutics Wins The Scientists Top 10 Innovations of 2019 Award for its Janus Base Technology GlobeNewswire +8.00%
Nov-25-19 08:00AM	NeuBase Therapeutics to Present at Upcoming Investor Conferences in December GlobeNewswire
Nov-24-19 04:30PM	NeuBase Therapeutics, Inc. (NBSE): Hedge Funds Dropped The Ball? Insider Monkey
Nov-12-19 09:16AM	NeuBase Therapeutics to Present at the Stifel 2019 Healthcare Conference GlobeNewswire
Oct-17-19 08:00AM	NeuBase Therapeutics Announces Issuance of Foundational Patent Covering the Key Building Blocks of PATrOL Enabled Therapies GlobeNewswire
Oct-11-19 08:00AM	NeuBase Therapeutics Announces Appointment of Cancer Biologist and RNA Therapeutics Specialist Steven Dowdy, Ph.D., to Scientific Advisory Board GlobeNewswire
Sep-26-19 09:08AM	NeuBase Therapeutics to Present at the Chardan 3rd Annual Genetic Medicines Conference GlobeNewswire -5.66%
Sep-21-19 11:25AM	Micro-Cap Rodeo Investor Conference October in Austin Texas ACCESSWIRE
Sep-09-19 08:39AM	NeuBase Therapeutics Hosting Key Opinion Leader Meeting on Huntington's Disease and PATrOL-Enabled Therapy on September 16th GlobeNewswire
Aug-14-19 04:05PM	NeuBase Therapeutics Reports Financial Results for the Fiscal Third Quarter of 2019 GlobeNewswire -5.97%
Aug-07-19 08:00AM	NeuBase Therapeutics to Ring the NASDAQ Closing Bell Today GlobeNewswire
Jul-30-19 08:00AM	NeuBase Therapeutics Announces Addition of Industry Pioneer Dr. Samuel Broder and World-Renowned Geneticist Dr. George Church to Scientific Advisory Board GlobeNewswire +8.47%
Jul-24-19 08:00AM	NeuBase Therapeutics Appoints Danith Ly, Ph.D. as Chief Scientific Officer GlobeNewswire
Jul-15-19 10:20AM	NeuBase Therapeutics Initiates Trading on NASDAQ Under Ticker Symbol NBSE GlobeNewswire -15.58%

NeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Stephan Dietrich A	CEO	Sep 28	Option Exercise	0.00	750,000	825	816,775	Sep 30 07:45 PM
Mann William Roland	Chief Operating Officer	Mar 30	Buy	1.92	6,200	11,904	11,200	Apr 01 04:16 PM
Branning Todd P.	Chief Financial Officer	Mar 18	Buy	1.81	10,000	18,100	30,000	Mar 21 04:06 PM
Branning Todd P.	Chief Financial Officer	Mar 17	Buy	1.74	10,000	17,400	20,000	Mar 18 04:11 PM
Branning Todd P.	Chief Financial Officer	Mar 16	Buy	1.62	10,000	16,200	10,000	Mar 18 04:11 PM
RICHMAN ERIC I	Director	Mar 04	Buy	1.62	1,000	1,620	44,960	Mar 07 07:13 PM
RICHMAN ERIC I	Director	Mar 03	Buy	1.72	1,300	2,236	43,960	Mar 07 07:13 PM
RICHMAN ERIC I	Director	Mar 01	Buy	1.58	1,580	2,496	42,660	Mar 07 07:13 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience